Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema

NCT05224102 is registered in ClinicalTrials.gov with Genentech, Inc. as lead sponsor.

NCT NCT05224102
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05224102 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IV, Multicenter, Open-Label, Single-Arm Study to Investigate Faricimab (RO6867461) Treatment Response in Treatment-Naive, Underrepresented Patients With Diabetic Macular Edema
Lead sponsor
Genentech, Inc.
Phase
Phase 4
Overall status
Active, not recruiting
Start date
February 28, 2022
Completion date
January 26, 2027
Enrollment
218 (estimated)
Sites
43

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic macular edema